Eli Lilly and (NYSE:LLY) Downgraded to Buy at StockNews.com

Eli Lilly and (NYSE:LLYGet Rating) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Saturday.

Other research analysts have also issued reports about the stock. The Goldman Sachs Group boosted their price target on shares of Eli Lilly and from $234.00 to $264.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. DZ Bank raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $291.00 price target for the company in a report on Friday, January 21st. Mizuho cut their price target on Eli Lilly and from $302.00 to $293.00 and set a “buy” rating for the company in a report on Friday, February 4th. Daiwa Capital Markets began coverage on Eli Lilly and in a research note on Thursday, March 10th. They issued an “outperform” rating and a $286.00 target price for the company. Finally, Bank of America upped their target price on Eli Lilly and from $300.00 to $315.00 in a research note on Thursday, March 17th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $299.06.

NYSE LLY opened at $292.13 on Friday. The company has a debt-to-equity ratio of 1.68, a quick ratio of 0.97 and a current ratio of 1.23. The firm has a market cap of $278.21 billion, a PE ratio of 47.58, a P/E/G ratio of 2.33 and a beta of 0.43. Eli Lilly and has a one year low of $181.19 and a one year high of $314.00. The firm’s fifty day moving average is $281.25 and its two-hundred day moving average is $262.96.

Eli Lilly and (NYSE:LLYGet Rating) last posted its quarterly earnings data on Thursday, April 28th. The company reported $2.62 EPS for the quarter, beating analysts’ consensus estimates of $2.32 by $0.30. The company had revenue of $7.81 billion for the quarter, compared to analyst estimates of $7.29 billion. Eli Lilly and had a net margin of 19.71% and a return on equity of 96.36%. Eli Lilly and’s quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the business posted $1.87 earnings per share. Research analysts predict that Eli Lilly and will post 8.78 earnings per share for the current year.

In related news, SVP Ilya Yuffa sold 1,000 shares of the stock in a transaction that occurred on Tuesday, February 15th. The shares were sold at an average price of $237.45, for a total value of $237,450.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CAO Donald A. Zakrowski sold 1,660 shares of the stock in a transaction on Friday, February 25th. The shares were sold at an average price of $243.84, for a total value of $404,774.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,088,551 shares of company stock valued at $307,943,730. Insiders own 0.12% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. State Street Corp grew its holdings in shares of Eli Lilly and by 2.5% in the 4th quarter. State Street Corp now owns 33,929,864 shares of the company’s stock valued at $9,372,107,000 after acquiring an additional 813,983 shares in the last quarter. Capital World Investors increased its position in shares of Eli Lilly and by 13.9% in the fourth quarter. Capital World Investors now owns 19,115,896 shares of the company’s stock worth $5,280,206,000 after purchasing an additional 2,325,514 shares during the period. Geode Capital Management LLC boosted its stake in Eli Lilly and by 2.9% in the fourth quarter. Geode Capital Management LLC now owns 14,731,168 shares of the company’s stock valued at $4,059,130,000 after buying an additional 409,009 shares in the last quarter. Jennison Associates LLC boosted its stake in Eli Lilly and by 10.7% in the third quarter. Jennison Associates LLC now owns 9,864,516 shares of the company’s stock valued at $2,279,196,000 after buying an additional 953,521 shares in the last quarter. Finally, Norges Bank acquired a new stake in Eli Lilly and in the fourth quarter valued at about $2,213,765,000. 82.16% of the stock is currently owned by institutional investors and hedge funds.

About Eli Lilly and (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

See Also

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.